Top

Published in:

Open Access 01-01-2014 | Topic Review

Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours

Authors: Justyna Kmiecik, Jacques Zimmer, Martha Chekenya

Published in: Journal of Neuro-Oncology | Issue 1/2014

Abstract

Natural killer (NK) cells are lymphocytes that play an important role in anti-tumour immunity. Their potential against brain cancer has been demonstrated in vitro and in vivo, both as a direct anti-tumour agent and in experimental therapies stimulating endogenous NK cell cytotoxicity. However, the clinical translation of these promising results requires detailed knowledge about the immune status of brain tumour patients, with focus on the NK cell population. In this report, we provide an overview of the studies investigating NK cell infiltration into the tumour, emphasizing the need of revision of the methodologies and further research in this field. We also discuss the potential of using autologous or allogeneic NK cells as effector cells in cellular therapy against brain cancer and developing immunotherapies stimulating endogenous NK cell-mediated anti-tumour response, such as blocking inhibitory killer immunoglobulin-like receptors. Combination of NK cell adoptive transfer with targeted therapies, such as anti-EGFR therapeutic antibody (CetuximAb) could also be a potent strategy.

Ali-Osman F (ed) (2005) Brain tumors. Humana Press, New Jersey

Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumours diagnosed in the United States in 2005–2009. Neuro-oncology 14(Suppl 5):v1–v49PubMedCentralPubMedCrossRef

Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France

Dunn GP, Dunn IF, Curry WT (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7:12PubMed

Yang I, Han SJ, Kaur G, Crane C, Parsa AT (2010) The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci 17:6–10PubMedCentralPubMedCrossRef

Sonabend AM, Rolle CE, Lesniak MS (2008) The role of regulatory T cells in malignant glioma. Anticancer Res 28:1143–1150PubMed

Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? the example of natural killer cells. Science 331:44–49PubMedCentralPubMedCrossRef

Seidel UJ, Schlegel P, Lang P (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumour immunotherapy with therapeutic antibodies. Front Immunol 4:76PubMedCentralPubMedCrossRef

Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495–502PubMedCentralPubMedCrossRef

10.

Vivier E, Nunes JA, Vely F (2004) Natural killer cell signaling pathways. Science 306:1517–1519PubMedCrossRef

11.

Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG (1998) Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 187:813–818PubMedCentralPubMedCrossRef

12.

Purdy AK, Campbell KS (2009) Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 8:2211–2220PubMedCrossRef

13.

Thielens A, Vivier E, Romagne F (2012) NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 24:239–245PubMedCrossRef

14.

Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197–223PubMedCrossRef

15.

Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M (2000) Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 61:7–17PubMedCrossRef

16.

Topham NJ, Hewitt EW (2009) Natural killer cell cytotoxicity: how do they pull the trigger? Immunology 128:7–15PubMedCrossRef

17.

Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420–430PubMedCrossRef

18.

Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27:5932–5943PubMedCrossRef

19.

Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850–861PubMedCrossRef

20.

Hsia JY, Chen JT, Chen CY, Hsu CP, Miaw J, Huang YS, Yang CY (2005) Prognostic significance of intratumoural natural killer cells in primary resected esophageal squamous cell carcinoma. Chang Gung Med J 28:335–340PubMed

21.

Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88:577–583PubMedCrossRef

22.

Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M (2003) Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 20:445–451PubMedCrossRef

23.

Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH (2007) Groupe d’etude des lymphomes de la: peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol 18:1209–1215PubMedCrossRef

24.

Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Callol L (2002) Prognostic significance of tumour infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35:23–28PubMedCrossRef

25.

Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182:3530–3539PubMedCrossRef

26.

Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V (2012) Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol 22:159–174PubMedCrossRef

27.

Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M (2004) RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64:7596–7603PubMedCrossRef

28.

Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B (2010) Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res 16:3399–3408PubMedCentralPubMedCrossRef

29.

Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M (2013) Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget 4(9):1507–1526

30.

Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T (2004) Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24:1861–1871PubMed

31.

Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri MA, Chiocca EA (2012) NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 18:1827–1834PubMedCentralPubMedCrossRef

32.

Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, Rhodes CH, Wishart HA, Lewis LD, Ernstoff MS (2011) Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 34:382–389PubMedCentralPubMedCrossRef

33.

Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumours. J Neuroimmunol 100:216–232PubMedCrossRef

34.

Parney I (2012) Basic concepts in glioma immunology. In: Yamanaka R (ed) Glioma. Springer, New York, pp 42–52CrossRef

35.

Servadei F, Parente R, Bucci M, Beltrandi E, Tognetti F, Gaist G (1983) Particular features of cell-mediated immunity in patients with anaplastic gliomas. A comparison with kidney and bladder cancer patients. J Neurooncol 1:327–332PubMedCrossRef

36.

Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT (2010) TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-oncology 12:7–13PubMedCentralPubMedCrossRef

37.

Dietrich J, Rao K, Pastorino S, Kesari S (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 4:233–242PubMedCentralPubMedCrossRef

38.

Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS (2011) Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-oncology 13:393–400PubMedCentralPubMedCrossRef

39.

Stevens A, Kloter I, Roggendorf W (1988) Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 61:738–743PubMedCrossRef

40.

Vaquero J, Coca S, Escandon J, Magallon R, Martinez R (1990) Immunohistochemical study of IOT-10 natural killer cells in brain metastases. Acta Neurochir 104:17–20PubMedCrossRef

41.

Vaquero J, Zurita M, Coca S (2012) Clinical behavior in metastatic brain disease is not influenced by the immunological defense mediated by CD57 NK-cells. Int J Surg Oncol 2012:834852PubMedCentralPubMed

42.

Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116:3865–3874PubMedCrossRef

43.

Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT (2011) Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg 115:505–511PubMedCrossRef

44.

Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164:1148–1152PubMed

45.

Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PO, Zimmer J, Chekenya M (2013) Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. doi:10.1016/j.jneuroim.2013.08.013

46.

Rossi ML, Esiri MM, Jones NR, Coakham HB, Moss TH, Cruz-Sanchez FF, Carey MP (1991) Characterization of the mononuclear cell infiltrate and HLA-Dr expression in 19 oligodendrogliomas. Surg Neurol 36:119–125PubMedCrossRef

47.

Domingues PH, Teodosio C, Ortiz J, Sousa P, Otero A, Maillo A, Barcena P, Garcia-Macias MC, Lopes MC, de Oliveira C, Orfao A, Tabernero MD (2012) Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. Am J Pathol 181:1749–1761PubMedCrossRef

48.

Chiu TL, Lin SZ, Hsieh WH, Peng CW (2009) AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells. Int J Oncol 35:1361–1367PubMed

49.

Pellegatta S, Eoli M, Frigerio S, Antozzi C, Bruzzone MG, Cantini G, Nava S, Anghileri E, Cuppini L, Cuccarini V, Ciusani E, Dossena M, Pollo B, Mantegazza R, Parati EA, Finocchiaro G (2013) The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology 2:e23401PubMedCentralPubMedCrossRef

50.

Zhang Z, Su T, He L, Wang H, Ji G, Liu X, Zhang Y, Dong G (2012) Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma. Tohoku J Exp Med 226:59–68PubMedCrossRef

51.

de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, Jafferji I, Trowsdale J, Liefers GJ, van de Velde CJ, Kuppen PJ (2012) NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12:24PubMedCentralPubMedCrossRef

52.

Vauleon E, Avril T, Collet B, Mosser J, Quillien V (2010) Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010:2010. doi:10.1155/2010/689171. Epub 2010 Oct 4

53.

Ishikawa E, Takano S, Ohno T, Tsuboi K (2012) Adoptive cell transfer therapy for malignant gliomas. Adv Exp Med Biol 746:109–120PubMedCrossRef

54.

Sankhla SK, Nadkarni JS, Bhagwati SN (1996) Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 27:133–140PubMedCrossRef

55.

Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175–182PubMedCrossRef

56.

Jachimowicz RD, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, Hansen HP, Reiners KS, Marie M, von Strandmann EP, Rothe A (2011) Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. Mol Cancer Ther 10:1036–1045PubMedCrossRef

57.

Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS (2012) A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120:4324–4333PubMedCrossRef

58.

Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A, Moretta L (2013) Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 4:15PubMedCentralPubMedCrossRef

59.

Bignon JD, Gagne K (2005) KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 17:553–559PubMedCrossRef

60.

Poli A KJ, Domingues O, Hentges F, Blery M, Chekenya M, Boucraut J, Zimmer J (2013) Natural killer cells in central nervous system disorders. J Immunol 190(11):5355–5362. doi:10.4049/jimmunol.1203401

61.

Zou JP, Morford LA, Chougnet C, Dix AR, Brooks AG, Torres N, Shuman JD, Coligan JE, Brooks WH, Roszman TL, Shearer GM (1999) Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162:4882–4892PubMed

62.

Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10:133–146PubMedCentralPubMed

Title: Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours
Authors: Justyna Kmiecik
Jacques Zimmer
Martha Chekenya
Publication date: 01-01-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1265-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Factors associated with a higher rate of distant failure after primary treatment for glioblastoma

The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection

Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas

Favorable survival and metabolic outcome for children with diencephalic syndrome using a radiation-sparing approach

Gross total resection improves overall survival in children with choroid plexus carcinoma

Double suicide gene therapy using human neural stem cells against glioblastoma: double safety measures